Generic Name and Formulations:
Febuxostat 40mg, 80mg; tabs.
Takeda Pharmaceutical Company
Indications for ULORIC:
Chronic management of hyperuricemia in patients with gout.
≥18yrs: initially 40mg once daily. Obtain target serum uric acid levels <6mg/dL after 2 weeks of initiating therapy; if not <6mg/dL, may increase to 80mg once daily. Gout flare prophylaxis, with an NSAID or colchicine, upon initiation of therapy and for up to 6 months, is recommended. Severe renal impairment: max 40mg once daily.
<18yrs: not established.
Concomitant azathioprine, mercaptopurine.
Not for treating asymptomatic hyperuricemia. Cardiovascular events: monitor for signs and symptoms of MI and stroke. Measure LFTs at baseline and if liver injury is suspected; interrupt therapy if ALT>3xULN and investigate cause. Do not restart if ALT>3xULN with serum total bilirubin >2xULN without alternative etiologies; for lesser elevations, use with caution. Severe hepatic impairment. Severe renal impairment (see Adult) or ESRD on dialysis. Secondary hyperuricemia (eg, Lesch-Nyhan syndrome, malignant disease, or in organ transplant recipients): not recommended. Discontinue if serious skin reactions are suspected (eg, DRESS, TEN). Pregnancy. Nursing mothers.
Xanthine oxidase inhibitor.
See Contraindications. Potentiates xanthine oxidase substrate drugs (eg, theophylline).
Abnormal LFTs, nausea, arthralgia, rash; gout flares, hepatic failure.
Tabs 40mg—30, 90, 500; 80mg—30, 100, 1000
Endocrinology Advisor Articles
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Trends in Bisphosphonate Use and Hip Fracture Rates in Denmark
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look
- FDA Committee Votes on Oral T1D Treatment Sotagliflozin
- Elevated Plasma Agouti-Related Protein May Be a Marker for Cushing Disease
- Therapeutic Effect of Long-Chain PUFA Omega 3 Supplementation in Obese Children
- Poor Health Outcomes Associated With Fear of Crime, Violence Among College Students of Color
- Safety of PCSK9 Inhibitors After Heart Transplantation Examined